Compile Data Set for Download or QSAR
maximum 50k data
Found 89 with Last Name = 'vander heiden' and Initial = 'mg'
TargetD-3-phosphoglycerate dehydrogenase(Homo sapiens (Human))
Whitehead Institute For Biomedical Research

LigandPNGBDBM195606(NCT-503)
Affinity DataIC50:  2.50E+3nMpH: 8.0 T: 2°CAssay Description:PHGDH assay buffer contained 50 mM TEA pH 8.0, 10 mM MgCl2, 0.05% BSA, and 0.01% Tween-20. PHGDH enzyme buffer consisted of assay buffer with 20 nM P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD-3-phosphoglycerate dehydrogenase(Homo sapiens (Human))
Whitehead Institute For Biomedical Research

LigandPNGBDBM195605(NCT-502 | US11225469, Compound 72)
Affinity DataIC50:  3.70E+3nMpH: 8.0 T: 2°CAssay Description:PHGDH assay buffer contained 50 mM TEA pH 8.0, 10 mM MgCl2, 0.05% BSA, and 0.01% Tween-20. PHGDH enzyme buffer consisted of assay buffer with 20 nM P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM82190(Salicylic acid derivative, compound 2)
Affinity DataIC50:  7.00E+3nMAssay Description:Primary screening was performed using PKM2 in the presence of FBP. Compounds were chosen as potential "hits" if the compound demonstrated inhibition ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM138386(US8877791, B1)
Affinity DataIC50:  1.00E+4nMAssay Description:Primary screening was performed using PKM2 in the presence of FBP. Compounds were chosen as potential "hits" if the compound demonstrated inhibition ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50261993(5-(methylthio)thiophene-2-carboxylic acid | CHEMBL...)
Affinity DataIC50:  1.00E+4nMAssay Description:Primary screening was performed using PKM2 in the presence of FBP. Compounds were chosen as potential "hits" if the compound demonstrated inhibition ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetD-3-phosphoglycerate dehydrogenase(Homo sapiens (Human))
Whitehead Institute For Biomedical Research

LigandPNGBDBM58473(MLS001172437 | N-(4-methyl-2-pyridinyl)-4-[3-(trif...)
Affinity DataIC50:  1.53E+4nMpH: 8.0 T: 2°CAssay Description:PHGDH assay buffer contained 50 mM TEA pH 8.0, 10 mM MgCl2, 0.05% BSA, and 0.01% Tween-20. PHGDH enzyme buffer consisted of assay buffer with 20 nM P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM138387(US8877791, D1)
Affinity DataIC50:  2.00E+4nMAssay Description:Primary screening was performed using PKM2 in the presence of FBP. Compounds were chosen as potential "hits" if the compound demonstrated inhibition ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetD-3-phosphoglycerate dehydrogenase(Homo sapiens (Human))
Whitehead Institute For Biomedical Research

LigandPNGBDBM195607(PHGDH-inactive | US11225469, Compound 71)
Affinity DataIC50: >5.70E+4nMpH: 8.0 T: 2°CAssay Description:PHGDH assay buffer contained 50 mM TEA pH 8.0, 10 mM MgCl2, 0.05% BSA, and 0.01% Tween-20. PHGDH enzyme buffer consisted of assay buffer with 20 nM P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM138388(US8877791, G1)
Affinity DataIC50:  7.00E+4nMAssay Description:Primary screening was performed using PKM2 in the presence of FBP. Compounds were chosen as potential "hits" if the compound demonstrated inhibition ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM138389(US8877791, H1)
Affinity DataIC50:  9.00E+4nMAssay Description:Primary screening was performed using PKM2 in the presence of FBP. Compounds were chosen as potential "hits" if the compound demonstrated inhibition ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM138385(US8877791, A1)
Affinity DataIC50:  9.00E+4nMAssay Description:Primary screening was performed using PKM2 in the presence of FBP. Compounds were chosen as potential "hits" if the compound demonstrated inhibition ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM11995(2-chloro-5-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic ac...)
Affinity DataIC50: >1.00E+5nMAssay Description:Primary screening was performed using PKM2 in the presence of FBP. Compounds were chosen as potential "hits" if the compound demonstrated inhibition ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361482(CHEMBL1939121)
Affinity DataEC50:  6.10E+3nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361483(CHEMBL1939120)
Affinity DataEC50:  6.10E+3nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361484(CHEMBL1939119)
Affinity DataEC50:  7.43E+3nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361485(CHEMBL1939118)
Affinity DataEC50:  6.60E+3nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361486(CHEMBL1939117)
Affinity DataEC50:  210nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361487(CHEMBL1939116)
Affinity DataEC50:  90nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361488(CHEMBL1939115)
Affinity DataEC50:  70nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361489(CHEMBL1939114)
Affinity DataEC50:  290nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361490(CHEMBL1939113)
Affinity DataEC50:  130nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361491(CHEMBL1939112)
Affinity DataEC50:  60nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361492(CHEMBL1939111)
Affinity DataEC50:  240nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361493(CHEMBL1939110)
Affinity DataEC50:  90nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361494(CHEMBL1939109)
Affinity DataEC50:  600nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361495(CHEMBL1939108)
Affinity DataEC50:  140nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361496(CHEMBL1939107)
Affinity DataEC50:  170nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361497(CHEMBL1939106)
Affinity DataEC50:  880nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361496(CHEMBL1939107)
Affinity DataEC50:  230nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361498(CHEMBL1939104)
Affinity DataEC50:  180nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361499(CHEMBL1939103)
Affinity DataEC50:  2.10E+3nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361500(CHEMBL1939102)
Affinity DataEC50:  570nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361501(CHEMBL1939101)
Affinity DataEC50:  1.83E+4nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361502(CHEMBL1939100)
Affinity DataEC50: >2.00E+4nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361503(CHEMBL1939099)
Affinity DataEC50:  510nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361504(CHEMBL1939098)
Affinity DataEC50:  440nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361505(CHEMBL1939097)
Affinity DataEC50:  3.80E+3nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361506(CHEMBL1939096)
Affinity DataEC50:  220nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361507(CHEMBL1939095)
Affinity DataEC50:  210nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361508(CHEMBL1939094)
Affinity DataEC50:  260nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361509(CHEMBL1939093)
Affinity DataEC50:  480nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361510(CHEMBL1939092)
Affinity DataEC50: >2.00E+4nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361511(CHEMBL1939091)
Affinity DataEC50: >2.00E+4nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361512(CHEMBL1939090)
Affinity DataEC50:  440nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361513(CHEMBL1939089)
Affinity DataEC50:  290nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361514(CHEMBL1939088)
Affinity DataEC50:  540nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361515(CHEMBL1939087)
Affinity DataEC50:  560nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361516(CHEMBL1939086)
Affinity DataEC50:  1.30E+3nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361517(CHEMBL1939085)
Affinity DataEC50:  100nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPyruvate kinase PKM(Homo sapiens (Human))
Beth Israel Deaconess Medical Center

US Patent
LigandPNGBDBM50361518(CHEMBL1939084)
Affinity DataEC50:  4.60E+3nMAssay Description:Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 89 total ) | Next | Last >>
Jump to: